Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients

• Published in: Journal of laboratory physicians 2015-07, Vol.7 (2), p.116-120
• Main Authors: Lakshmaiah, Kuntegowdanahalli C, Malabagi, Abhayakumar S, Shetty, Rachan, Sinha, Mahua, Jayashree, Rudrapatna S
• Format: Article
• Language: English
• Subjects: antibiotics; Care and treatment; Clinical outcomes; Diagnosis; febrile neutropenia; Fever; gram-negative organism; hematological malignancies; Hematology; Leukemia; Leukocytes; Microbiology; Neutropenia; Original; Original Article; Patient outcomes; treatment
• ISSN: 0974-2727; 0974-7826
• DOI: 10.4103/0974-2727.163126

ABSTRACT Background and Objectives: Febrile neutropenia (FN) is considered a medical emergency. Patients with hematological malignancies (HM) commonly experience FN. Broad spectrum antibiotics have to be started empirically to prevent complications. This study depicts the clinical profile, microbiological profile, antibiotic sensitivity pattern, and outcome in high risk HM. Materials and Methods: In this prospective study, 72 patients with hematologic malignancies, diagnosed and treated for 108 high risk febrile neutropenic episodes from August 2011 to January 2013 at a Regional Cancer Center, in South India were analyzed. Cefoperazone-sulbactum was used as a first-line empiric antibiotic. Results: Majority of the patients with FN episodes had acute myeloid leukemia. Overall culture positivity was 29.62%. The most common organisms isolated were Gram-negative bacilli (63.64%), with Escherichia coli being the most frequent pathogen. All Gram-negative organisms were sensitive to imipenem, whereas sensitivity pattern to other antibiotics were as follows: 85.71%, 78.26%, 69.52%, 63.64%, 41.66% and 47.05% for pipercillin-tazoactum, meropenem, cefoperazone-sulbactum, amikacin, ceftazidime, ciprofloxacin respectively. Overall mortality was 13.5%. Most of the patients responded to empiric antibiotic cefoperazone-sulbactum. Conclusions: In the hematologic malignancies particularly in acute leukemia, there is high risk of developing FN. Empiric therapy with cefoperazone-sulbactum as a first line leads to satisfactory outcome in high risk FN and therapy should be tailored to the most appropriate antibiotics according to the bacterial culture results.